Outcomes of systemic therapy for patients with metastatic angiosarcoma Journal Article

Authors: D'Angelo, S. P.; Munhoz, R. R.; Kuk, D.; Landa, J.; Hartley, E. W.; Bonafede, M.; Dickson, M. A.; Gounder, M.; Keohan, M. L.; Crago, A. M.; Antonescu, C. R.; Tap, W. D.
Article Title: Outcomes of systemic therapy for patients with metastatic angiosarcoma
Abstract: Background: Angiosarcomas (AS) are rare tumors of vascular origin with a variable behavior and overall poor prognosis. We sought to assess the outcomes of patients treated for metastatic disease. Methods: We performed a retrospective analysis of 119 patients treated for metastatic AS. Outcomes and efficacy measurements of the first and subsequent lines of treatment were analyzed. Results: Median age was 61 years, and the most frequent primary sites were chest wall/breast (31%), viscera (22%) and head/neck (20%). Seventy-three (61%) and 46 (39%) patients received ≥2 and ≥3 lines of therapy, respectively. The most commonly used agents included taxanes and anthracyclines. Median overall survival was 12.1 months. Median times to tumor progression were 3.5 months for first line, 3.7 months for second line and 2.7 months for third line. Among 48 patients evaluable per RECIST, the overall response rate to first line was 30% and <10% in subsequent lines. Doxorubicin, liposomal doxorubicin and taxanes resulted in similar response rates and survival, and there was no apparent benefit for combination chemotherapy. Conclusion: Despite reasonable response rates in the first-line setting, benefit from systemic therapy is short-lived in metastatic AS, and outcomes are poor. Doxorubicin, liposomal doxorubicin and taxanes are reasonable and appropriate choices for monotherapy. © 2015 S. Karger AG, Basel.
Keywords: adult; cancer survival; treatment response; major clinical study; overall survival; sorafenib; bevacizumab; doxorubicin; sunitinib; cancer combination chemotherapy; cancer growth; multimodality cancer therapy; systemic therapy; gemcitabine; paclitaxel; cancer radiotherapy; chemotherapy; temozolomide; cancer staging; outcome assessment; follow up; dacarbazine; metastasis; multiple cycle treatment; angiosarcoma; retrospective study; ifosfamide; electronic medical record; soft tissue sarcoma; platinum; navelbine; everolimus; brivanib; human; male; female; priority journal; article
Journal Title: Oncology
Volume: 89
Issue: 4
ISSN: 0030-2414
Publisher: S. Karger AG  
Date Published: 2015-09-01
Start Page: 205
End Page: 214
Language: English
DOI: 10.1159/000381917
PROVIDER: scopus
PUBMED: 26043723
PMCID: PMC5587158
Notes: Export Date: 2 November 2015 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Cristina R Antonescu
    612 Antonescu
  2. Jonathan Landa
    21 Landa
  3. Mary Louise Keohan
    66 Keohan
  4. Mrinal M Gounder
    74 Gounder
  5. Aimee Marie Crago
    57 Crago
  6. Mark Andrew Dickson
    79 Dickson
  7. Deborah Kuk
    81 Kuk
  8. William Douglas Tap
    129 Tap
  9. Rodrigo Ramella Munhoz
    15 Munhoz